199 results on '"Caronna, Edoardo"'
Search Results
2. Early and annual projected savings from anti-CGRP monoclonal antibodies in migraine prevention: a cost-benefit analysis in the working-age population
3. CGRP monoclonal antibodies and CGRP receptor antagonists (Gepants) in migraine prevention
4. Headache in COVID-19 and Long COVID: to Know Facts for Clinical Practice
5. The state of art on the use of patient reported outcomes in migraine
6. Mode and site of action of therapies targeting CGRP signaling
7. Exploring sensory sensitivity, cortical excitability, and habituation in episodic migraine, as a function of age and disease severity, using the pattern-reversal task
8. Evaluación de la calidad y manejo de la cefalea en un paciente ingresado en el área de Neurociencia. Estudio CALMA
9. Effectiveness and Safety of OnabotulinumtoxinA in Adolescent Patients with Chronic Migraine
10. Reply to the letter: Headaches during/after SARS‐CoV‐2 infection/vaccination can be primary and secondary as well as acute and chronic, by Finsterer J and Mehri S
11. Epidemiology, work and economic impact of migraine in a large hospital cohort: time to raise awareness and promote sustainability
12. The impact of anti-CGRP monoclonal antibodies in resistant migraine patients: a real-world evidence observational study
13. Incidence of Status Migrainosus in Olmsted County, Minnesota, United States: Characterization and Predictors of Recurrence
14. Headaches and facial pain attributed to SARS‐CoV‐2 infection and vaccination: a systematic review
15. Quantifying sensory thresholds along the migraine cycle: An exploratory longitudinal study
16. Improvement of migraine depressive symptoms is not related to headache frequency: exploring the impact of anti-CGRP therapies
17. Migraine worsening after COVID‐19 and COVID‐19 vaccination: Are we facing a nocebo effect?
18. Cortical metabolic and structural differences in patients with chronic migraine. An exploratory 18FDG-PET and MRI study
19. In search of a gold standard patient-reported outcome measure to use in the evaluation and treatment-decision making in migraine prevention. A real-world evidence study
20. Anti-CGRP monoclonal antibodies in chronic migraine with medication overuse: real-life effectiveness and predictors of response at 6 months
21. Headache as a Symptom of COVID-19: Narrative Review of 1-Year Research
22. Impact of anti-CGRP monoclonal antibodies on migraine attack accompanying symptoms: A real-world evidence study
23. Chapter 7 - CGRP monoclonal antibodies and CGRP receptor antagonists (Gepants) in migraine prevention
24. Effectiveness and safety of anti-CGRP monoclonal antibodies in patients over 65 years: a real-life multicentre analysis of 162 patients
25. Patterns of response toanti‐CGRPmonoclonal antibodies during first 6‐months of treatment in resistant migraine patients: impact on outcome
26. Redefining migraine prevention: early treatment with anti-CGRP monoclonal antibodies enhances response in the real world
27. Exploring sensory sensitivity, cortical excitability, and habituation using the pattern-reversal task across the episodic migraine spectrum: A case-control study
28. Virtual issue: COVID ‐19 and headache
29. Headache attributed to SARS-CoV-2 infection, vaccination and the impact on primary headache disorders of the COVID-19 pandemic: A comprehensive review
30. A study of differential microRNA expression profile in migraine: the microMIG exploratory study
31. Headache attributed to SARS-CoV-2 infection, vaccination and the impact on primary headache disorders of the COVID-19 pandemic : A comprehensive review
32. Patterns of response to anti‐calcitonin gene‐related peptide monoclonal antibodies during first 6 months of treatment in resistant migraine patients: Impact on outcome.
33. Efficacy and safety of galcanezumab as a treatment of refractory episodic and chronic cluster headache: Case series and narrative review
34. The relationship of headache as a symptom to COVID ‐19 survival: A systematic review and meta‐analysis of survival of 43,169 inpatients with COVID ‐19
35. Salivary CGRP and Erenumab Treatment Response: Towards Precision Medicine in Migraine
36. Avoidance behaviour modulates but does not condition phonophobia in migraine
37. Myasthenia gravis following alemtuzumab therapy for multiple sclerosis
38. La perspectiva del pacient com a criteri mèdic de la migranya
39. Headache attributed to SARS-CoV-2 infection, vaccination and the impact on primary headache disorders of the COVID-19 pandemic:A comprehensive review
40. Twenty twenty … two: Headache and COVID‐19
41. sj-pdf-2-cep-10.1177_03331024211068074 - Supplemental material for Post-COVID-19 persistent headache: A multicentric 9-months follow-up study of 905 patients
42. Headache attributed to COVID-19: an opportunity to advance in understanding the pathophysiology of headache disorders
43. sj-pdf-1-cep-10.1177_03331024221111772 - Supplemental material for Avoidance behaviour modulates but does not condition phonophobia in migraine
44. sj-pdf-1-cep-10.1177_03331024211068074 - Supplemental material for Post-COVID-19 persistent headache: A multicentric 9-months follow-up study of 905 patients
45. Incidence of Status Migrainosus in Olmsted County, Minnesota, United States: Characterization and Predictors of Recurrence.
46. Post-COVID-19 persistent headache: A multicentric 9-months follow-up study of 905 patients
47. Safety of anti-CGRP monoclonal antibodies in patients with migraine during the COVID-19 pandemic: present and future implications
48. Salivary CGRP can monitor the different migraine phases: CGRP (in)dependent attacks
49. Toward a better understanding of persistent headache after mild COVID‐19: Three migraine‐like yet distinct scenarios
50. Epidemiology, work and economic impact of migraine in a large hospital cohort: time to raise awareness and promote sustainability
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.